Skip to main content

5-HT2C Receptor Agonists and the Control of Appetite

  • Chapter
  • First Online:
Appetite Control

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 209))

Abstract

The role of serotonin (5-HT) in appetite control is well recognised. 5-HT drugs reduce food intake in rodents in a manner consistent with an enhancement of satiety. In humans, they have been shown to reduce caloric intake, an effect associated with reduced hunger and increased satiety. These effects appear to be mediated, at least in part, by the 5-HT2C receptor subtype. 5-HT-acting drugs such as fenfluramine, d-fenfluramine, and sibutramine have provided effective anti-obesity treatments in the past. However, more selective agents are needed that produce the same changes in eating behaviour and induce weight loss without unacceptable side effects. Lorcaserin, a selective 5-HT2C receptor agonist, is a novel anti-obesity agent that reduces both energy intake and body weight. The effects of lorcaserin on eating behaviour remain to be characterised as does its behavioural specificity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Abeniam L, Moride Y, Brenot F et al (1996) Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335:609–616

    Article  Google Scholar 

  • Arterburn DE, Crane PK, Veenstra DL (2004) The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 164:994–1003

    Article  PubMed  CAS  Google Scholar 

  • Bjenning C, Williams J, Whelan K et al (2004) Chronic oral administration of APD356 significantly reduces body weight and fat mass in obesity-prone (DIO) male and female rats. Int J Obes 28(suppl 1):214

    Google Scholar 

  • Blundell JE (1977) Is there a role for serotonin (5-hydroxytryptamine) in feeding? Int J Obes 1:15–42

    PubMed  CAS  Google Scholar 

  • Blundell JE, Halford JCG (1998) Serotonin and appetite regulation: implications for the treatment of obesity. CNS Drugs 9:473–495

    Article  CAS  Google Scholar 

  • Blundell JE, Hill AJ (1990) Sensitivity of the appetite control system in obese subjects to nutritional and serotoninergic challenges. Int J Obes 14:219–233

    PubMed  Google Scholar 

  • Blundell JE, Latham CJ (1978) Pharmacological manipulation of feeding behaviour: possible influences of serotonin and dopamine on food intake. In: Garattini S, Samanin R (eds) Central mechanisms of anorectic drugs. Raven, NY, pp 83–109

    Google Scholar 

  • Blundell JE, Latham CJ (1980) Characteristic adjustments to the structure of feeding behaviour following pharmacological treatments: effects of amphetamine and fenfluramine and the antagonism by pimozide and metergoline. Pharmacol Biochem Behav 12:717–722

    Article  PubMed  CAS  Google Scholar 

  • Blundell JE, McArthur RA (1981) Behavioural flux and feeding: continuous monitoring of food intake and food selection, and the video-recording of appetitive and satiety sequences for the analysis of drug action. In: Samanin R, Garattini S (eds) Anorectic agents: mechanisms of action and tolerance. Raven, NY, pp 19–43

    Google Scholar 

  • Chapelot D, Mamonier C, Thomas F et al (2000) Modalities of the food intake-reducing effect of sibutramine in humans. Physiol Behav 68:299–308

    Article  PubMed  CAS  Google Scholar 

  • Clifton PG (1994) The neuropharmacology of meal patterning. In: Cooper SJ (ed) Ethology and psychopharmacology. Wiley, Chichester, pp 313–328

    Google Scholar 

  • Cowen PJ, Sargent PA, Williams C et al (1995) Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women. Hum Psychopharmacol 10:385–391

    Article  CAS  Google Scholar 

  • Goodall E, Silverstone T (1988) Differential effect of d-fenfluramine and metergoline on food intake in human subjects. Appetite 11:215–288

    Article  PubMed  CAS  Google Scholar 

  • Haddock CK, Poston WSC, Dill PL et al (2002) Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes 26:262–273

    Article  CAS  Google Scholar 

  • Halford JCG, Blundell JE (1993) 5-Hydroxytryptaminergic drugs compared on the behavioural sequence associated with satiety. Br J Pharmacol 100:95

    Google Scholar 

  • Halford JCG, Boyland EJ, Cooper SJ et al (2010a) The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. J Psychopharmacol 24:99–109

    Article  PubMed  CAS  Google Scholar 

  • Halford JCG, Boyland EJ, Blundell JE et al (2010b) Pharmacological management of human appetite expression: evaluating the effects of novel anti-obesity agents on eating behaviour. Nat Endocrine Rev 6:255–269

    Article  CAS  Google Scholar 

  • Halford JCG, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007) Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 67:27–55

    Article  PubMed  CAS  Google Scholar 

  • Halford JCG, Blundell JE (2000) Separate systems for serotonin and leptin in appetite control. Ann Med 32:222–232

    Article  PubMed  CAS  Google Scholar 

  • Halford JCG, Wanninayake SCD, Blundell JE (1998) Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 61:159–168

    Article  PubMed  CAS  Google Scholar 

  • Hansen DL, Toubro S, Stock MJ et al (1998) Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68:1180–1186

    PubMed  CAS  Google Scholar 

  • Hayashi A, Sonoda R, Kimura Y et al (2004) Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats. Brain Res 1011:221–227

    Article  PubMed  CAS  Google Scholar 

  • Heisler LK, Cowley MA, Tecott LH et al (2002) Activation of Central Melanocortin pathways by Fenfluramine. Science 297:609–611

    Article  PubMed  CAS  Google Scholar 

  • Heisler LK, Cowley MA, Kishi T et al (2003) Central serotonin and melanocortin pathways regulating energy homeostasis. N Y Acad Sci 994:169–174

    Article  CAS  Google Scholar 

  • Heisler LK, Jobst EE, Sutton GM et al (2006) Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 51:239–249

    Article  PubMed  CAS  Google Scholar 

  • Hewitt KN, Lee MD, Dourish CT et al (2002) Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 71:691–700

    Article  PubMed  CAS  Google Scholar 

  • Higgs S, Cooper AJ, Barnes NM (2011) Reversal of sibutramine-induced anorexia with a selective 5-HT2C receptor antagonist. Psychopharmacology 214:941–947

    Article  PubMed  CAS  Google Scholar 

  • Hoyer D, Martin G (1997) 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 36:419–428

    Article  PubMed  CAS  Google Scholar 

  • James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, SCOUT Investigators (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363:905–917

    Article  PubMed  CAS  Google Scholar 

  • Kennett GA, Curzon G (1988a) Evidence that the hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU-24969 only requires 5-HT1B receptors. Psychopharmacology 96:93–100

    Article  PubMed  CAS  Google Scholar 

  • Kennett GA, Curzon G (1988b) Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 94:137–147

    PubMed  CAS  Google Scholar 

  • Kitchener SJ, Dourish CT (1994) An examination of the behavioural specificity of hypophagia induced by 5-HT1B, 5-HT1C and 5-HT2 receptor agonists using the post-prandial sequence in rats. Psychopharmacology 113:368–377

    Article  Google Scholar 

  • Lawton CL, Wales JK, Hill AJ et al (1995) Serotoninergic manipulation, meal-induced satiety and eating patterns. Obes Res 3:345–356

    PubMed  CAS  Google Scholar 

  • Martin CK, Redman LM, Zhang J et al (2011) Lorcaserin, a 5-HT2C receptor agonist, reduced body weight by decreasing energy intake within influencing energy expenditure. J Clin Endocrinol Metab 96:837–45

    Article  PubMed  CAS  Google Scholar 

  • McGuirk J, Silverstone T (1990) The effect of 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int J Obes 14:361–372

    PubMed  CAS  Google Scholar 

  • Nonogaki K, Abdullah L, Goulding EH et al (2003) Hyperactivity and reduced energy cost of physical activity in serotonin 5-HT2C receptor mutant mice. Diabetes 52:315–320

    Article  PubMed  CAS  Google Scholar 

  • Padwal R, Li SK, Lau DCW (2003) Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes 27:1437–46

    Article  CAS  Google Scholar 

  • Pijl H, Koppeschaar HPF, Willekens FLA et al (1991) Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes 15:237–242

    PubMed  CAS  Google Scholar 

  • Rogers PJ, Blundell JE (1979) Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects. Psychopharmacology 66:159–165

    Article  PubMed  CAS  Google Scholar 

  • Rolls BJ, Shide DJ, Thorward ML et al (1998) Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 6:1–11

    PubMed  CAS  Google Scholar 

  • Sargent PA, Sharpley AL, Williams C et al (1997) 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133:309–312

    Article  PubMed  CAS  Google Scholar 

  • Smith SR, Prosser WA, Donahue DF et al (2009) Lorcaserin (APD356), a selective 5-HT2C agonist, reducing body weight in obese men and women. Obesity 17:494–500

    Article  PubMed  CAS  Google Scholar 

  • Smith SR, Wiessman NJ, Anderson CM et al (2010) Multicenter, placebo-controlled trial for Lorcaserin for weight management. N Engl J Med 363:245–56

    Article  PubMed  CAS  Google Scholar 

  • Tecott LH, Sun LM, Akanna SF et al (1995) Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374:542–546

    Article  PubMed  CAS  Google Scholar 

  • Vickers SP, Benwell KR, Porter RH et al (2000) Comparative effects of continuous infusion of mCPP, Ro 60–0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br J Pharmacol 130:1305–1314

    Article  PubMed  CAS  Google Scholar 

  • Vickers SP, Clifton PG, Dourish CT et al (1999) Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology 143:309–314

    Article  PubMed  CAS  Google Scholar 

  • Vickers SP, Dourish CT (2004) Serotonin receptor ligands and the treatment of obesity. Curr Opin Investig Drugs 5:377–388

    PubMed  CAS  Google Scholar 

  • Vickers SP, Dourish CT, Kennett GA (2001) Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41:200–209

    Article  PubMed  CAS  Google Scholar 

  • Vickers SP, Easton N, Webster LJ et al (2003) Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology 167:274–280

    PubMed  CAS  Google Scholar 

  • Walsh AE, Smith KA, Oldman AD (1994) M-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology 116:120–122

    Article  PubMed  CAS  Google Scholar 

  • Ward AS, Comer SD, Haney M et al (1999) Fluoxetine-maintained obese humans: effect on food intake and body weight. Physiol Behav 66:815–821

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jason C. G. Halford .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Halford, J.C.G., Harrold, J.A. (2012). 5-HT2C Receptor Agonists and the Control of Appetite. In: Joost, HG. (eds) Appetite Control. Handbook of Experimental Pharmacology, vol 209. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-24716-3_16

Download citation

Publish with us

Policies and ethics